The “Transfection Reagents and Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” Insights report has been added to ResearchAndMarkets.com’s offering.
The global transfection reagents and equipment market reached a value of US$ 824.2 Million in 2021. Looking forward, the publisher expects the market to reach US$ 1,322.50 Million by 2027, exhibiting a CAGR of 7.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Transfection reagents and equipment help modulate gene expression in eukaryotic cells in vitro and in vivo. They allow researchers to generate stable cell lines and introduce deoxyribonucleic acid (DNA) plasmids possessing gene inserts for expression and small interfering RNA (siRNA). They are currently being used as viable analytical tools for protein synthesis, cell growth and development, and facilitating the study of genetic functions. Besides this, as they provide cost-effective and rapid production of recombinant human therapeutic proteins in sufficient quantities, transfection reagents and equipment are also gaining traction in producing r-proteins, antibodies, and viral vectors for vaccines.
Due to the outbreak of coronavirus disease (COVID-19) globally, governing agencies of numerous countries are focusing on accelerating the vaccination drive. However, due to the emergence of new variants, the protection and immunity that these vaccines provide are short-lived. As a result, insights there is a rise in the need of transfection reagents and equipment to develop innovative strategies or alternatively repurpose existing treatments to fight against virus infection.
Apart from this, rapid detection of new cancer variants, coupled with the escalating demand for precision medicine and high-quality oncology care, are driving the adoption of transfection reagents and equipment in cancer research and drug development.
Moreover, the emerging use of gene therapies to treat rare diseases caused by genetic problems is impelling the market growth. Furthermore, insights due to the growing number of fatal road accidents across the globe, there is a significant rise in the demand for tissue engineering to develop functional substitutes for damaged tissues. This, in turn, is propelling the market growth. Besides this, recent advancements in transfection technologies, along with increasing investments in pharmaceutical and biotechnology sectors, are anticipated to drive the market.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., Lonza Group AG, MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OriGene Technologies Inc., PerkinElmer Inc., Polyplus-transfection SA, Promega Corporation, PromoCell GmbH, Qiagen N.V. and Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
How has the global transfection reagents and equipment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global transfection reagents and equipment market? What are the key regional markets? What is the breakup of the market based on the product? What is the breakup of the market based on the technology? What is the breakup of the market based on the application? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global transfection reagents and equipment market and who are the key players? What is the degree of competition in the industry?
This article was shared with Prittle Prattle News as a Press Release by PRNewswire
